{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:21:39Z","timestamp":1791638499117,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1084487"],"award-info":[{"award-number":["APP1084487"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DE130100117"],"award-info":[{"award-number":["DE130100117"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.bcp.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T15:03:01Z","timestamp":1490281381000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Capadenoson, a clinically trialed partial adenosine A 1 receptor agonist, can stimulate adenosine A 2B receptor biased agonism"],"prefix":"10.1016","volume":"135","author":[{"given":"Jo-Anne","family":"Baltos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Xue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren T.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2017.03.014_b0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2017.03.014_b0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0026-895X(24)12531-X","article-title":"Characterization of human A2B adenosine receptors: radioligand binding, western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells","volume":"56","author":"Linden","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0015","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1096\/fj.06-6419com","article-title":"HIF-dependent induction of adenosine A2B receptor in hypoxia","volume":"20","author":"Kong","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2017.03.014_b0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.molmed.2013.02.005","article-title":"Attenuating myocardial ischemia by targeting A2B adenosine receptors","volume":"19","author":"Eltzschig","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcp.2017.03.014_b0025","doi-asserted-by":"crossref","first-page":"12012","DOI":"10.1073\/pnas.1221733110","article-title":"Signaling through hepatocellular A2B adenosine receptors dampens ischemia and reperfusion injury of the liver","volume":"110","author":"Zimmerman","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2017.03.014_b0030","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1517\/14728220903241666","article-title":"Targeting the A2B adenosine receptor during gastrointestinal ischemia and inflammation","volume":"13","author":"Eltzschig","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2017.03.014_b0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1161\/01.HYP.31.4.943","article-title":"Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors","volume":"31","author":"Dubey","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2017.03.014_b0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.phrs.2015.06.015","article-title":"Adenosine receptors and diabetes: focus on the A2B adenosine receptor subtype","volume":"99","author":"Merighi","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2017.03.014_b0045","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.humpath.2010.04.008","article-title":"Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells","volume":"41","author":"Ma","year":"2010","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bcp.2017.03.014_b0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11302-012-9350-3","article-title":"A2B adenosine receptor blockade inhibits growth of prostate cancer cells","volume":"9","author":"Wei","year":"2013","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bcp.2017.03.014_b0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1101845","article-title":"Adenosine A2B receptor blockade slows growth of bladder and breast tumors","volume":"188","author":"Cekic","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2017.03.014_b0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/jm061170a","article-title":"Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9 h-purin-9-yl]- N-ethyl-\u03b2- d-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists","volume":"50","author":"Baraldi","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.03.014_b0065","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/med.20069","article-title":"Structure-affinity relationships of adenosine A2B receptor ligands","volume":"26","author":"Beukers","year":"2006","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2017.03.014_b0070","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.2174\/092986706779010306","article-title":"Ligands for A2B adenosine receptor subtype","volume":"13","author":"Baraldi","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2017.03.014_b0075","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/07328319808004215","article-title":"A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists","volume":"17","author":"de Zwart","year":"1998","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.bcp.2017.03.014_b0080","unstructured":"U. Rosentreter, R. Henning, M. Bauser, T. Kr\u00e4mer, A. Vaupel, W. H\u00fcbsch, et al., Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands, Bayer, Patent WO2001025210A2, 2001."},{"key":"10.1016\/j.bcp.2017.03.014_b0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11302-008-9097-z","article-title":"Recent improvements in the development of A2B adenosine receptor agonists","volume":"4","author":"Baraldi","year":"2008","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bcp.2017.03.014_b0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/jpet.113.210849","article-title":"BAY60-6583 acts as a partial agonist at adenosine A2B receptors","volume":"349","author":"Hinz","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.03.014_b0095","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/med.21318","article-title":"Biased agonism at G protein-coupled receptors: the promise and the challenges-a medicinal chemistry perspective","volume":"34","author":"Shonberg","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2017.03.014_b0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2017.03.014_b0105","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.03.014_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bcp.2015.11.013","article-title":"Quantification of adenosine A1 receptor biased agonism: implications for drug discovery","volume":"99","author":"Baltos","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0115","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1073\/pnas.1320962111","article-title":"Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist","volume":"111","author":"Valant","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2017.03.014_b0120","first-page":"1","article-title":"Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor","volume":"1","author":"Ben","year":"2013","journal-title":"Silico Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bcp.2014.05.008","article-title":"Probing biased\/partial agonism at the G protein-coupled A2B adenosine receptor","volume":"90","author":"Gao","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00392-012-0430-8","article-title":"The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina","volume":"101","author":"Tendera","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.bcp.2017.03.014_b0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11302-011-9274-3","article-title":"Partial adenosine A1 receptor agonists for cardiovascular therapies","volume":"8","author":"Albrecht-K\u00fcpper","year":"2011","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bcp.2017.03.014_b0140","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejmech.2015.07.023","article-title":"Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists","volume":"101","author":"Louvel","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.03.014_b0145","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.112.000208","article-title":"Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure","volume":"6","author":"Sabbah","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.bcp.2017.03.014_b0150","unstructured":"Bayer, Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days. In: ClinicalTrial.gov [Internet]. Bethesda (MD): National Library of Medicine (US), https:\/\/clinicaltrials.gov\/show\/NCT00568945 (accessed October 25, 2016)."},{"key":"10.1016\/j.bcp.2017.03.014_b0155","unstructured":"U. Rosentreter, T. Kramer, M. Shimada, W. Hubsch, N. Diedrichs, T. Krahn, et al., Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same, Bayer, Patent WO2003053441 A1, 2003."},{"key":"10.1016\/j.bcp.2017.03.014_b0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.109.158667","article-title":"Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity","volume":"331","author":"Stewart","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.03.014_b0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2164-12-14","article-title":"Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis","volume":"12","author":"Atwood","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bcp.2017.03.014_b0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/jpet.115.230003","article-title":"Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation","volume":"357","author":"Vecchio","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.03.014_b0175","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cardiores.2006.07.006","article-title":"Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes","volume":"72","author":"Laskowski","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2017.03.014_b0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1124\/mol.107.037630","article-title":"Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors","volume":"72","author":"May","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.116.103283","article-title":"Structure-activity analysis of biased agonism at the human adenosine A3 receptor","volume":"90","author":"Baltos","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0190","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0195","first-page":"1","article-title":"The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling","author":"Vecchio","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11302-015-9460-9","article-title":"Selectivity is species-dependent: characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors","volume":"11","author":"Alnouri","year":"2015","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bcp.2017.03.014_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.03.014_b0210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/cn200111m","article-title":"A simple method for quantifying functional selectivity and agonist bias","volume":"3","author":"Kenakin","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2017.03.014_b0215","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/mol.115.099770","article-title":"The effective application of biased signaling to new drug discovery","volume":"88","author":"Kenakin","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0220","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/mol.58.6.1349","article-title":"Why are A2B receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A2B receptor for 2-(1-Hexynyl)adenosine","volume":"58","author":"Beukers","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00005131","article-title":"Comparative pharmacology of human adenosine receptor subtypes \u2013 characterization of stably transfected receptors in CHO cells","volume":"357","author":"Klotz","year":"1998","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0230","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1021\/jm900413e","article-title":"1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity","volume":"52","author":"Borrmann","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.03.014_b0235","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1098-2299(199611\/12)39:3\/4<243::AID-DDR3>3.0.CO;2-R","article-title":"Molecular characterization of recombinant human adenosine receptors","volume":"39","author":"Robeva","year":"1996","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2017.03.014_b0240","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.tips.2007.06.002","article-title":"GPCR functional selectivity has therapeutic impact","volume":"28","author":"Mailman","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2017.03.014_b0245","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1161\/CIRCULATIONAHA.106.630087","article-title":"Long-term stimulation of adenosine A2B receptors begun after myocardial infarction prevents cardiac remodeling in rats","volume":"114","author":"Wakeno","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2017.03.014_b0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hrthm.2013.10.023","article-title":"Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model","volume":"11","author":"Zhang","year":"2014","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.bcp.2017.03.014_b0255","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1124\/mol.113.087742","article-title":"Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: a novel therapeutic approach for cardiac fibrosis","volume":"84","author":"Lu","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.014_b0260","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1067\/mlc.2000.105617","article-title":"Angiotensin II\u2013induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats","volume":"135","author":"Ikeda","year":"2000","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bcp.2017.03.014_b0265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00395-009-0056-9","article-title":"AMP579 is revealed to be a potent A2B-adenosine receptor agonist in human 293 cells and rabbit hearts","volume":"105","author":"Liu","year":"2009","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.bcp.2017.03.014_b0270","article-title":"Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure","author":"Voors","year":"2016","journal-title":"J. Clin. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:37:28Z","timestamp":1750163848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217301600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":54,"alternative-id":["S0006295217301600"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.03.014","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}